Introduction: The right treatment of male infertility is relatively costly procedure. So we should sincerer about the treatment procedure to evaluate the role of mast cell blocker ebastin in male infertility for the sake of the wellbeing of our people. The study aims to observe and evaluate the effect of Mast cell (MC) blocker Ebastin in the improvement of sperm motility in asthenospermic infertile male. Methods: This was a longitudinal clinical trial study and was conducted in the Infertility Unit outdoor, Department of obstetrics and gynecology, Bangabandhu Sheikh Mujib Medical University, Dhaka. Bangladesh during the period from January 2015 to December 2015. This study was conducted among the male patients and followed Purposive sampling technique. Finally, 334 cases were enrolled in this study. Among the male with abnormal semen parameter 168 patients were Asthenozospermic and 60 patients were combined Oligo-asthenozospermic. Statistical analysis was carried out by using the SPSS 16.0 & MS-Excel2016. Result: From 334 study people we found in group I, mean sperm total mortality was 24.86±12.02% in pretreatment and 34.29±9.35% in post treatment. The difference was statistically significant (p<0.05). In group II, mean sperm total mortality was 21.96±6.17% in pretreatment and 22.44±4.81% in post treatment. The difference was not statistically significant (p>0.05). Improved sperm motility was 75.4% of asthenozospermic male in ebastin group and 19.3% in placebo group. Which was statistically significant (p<0.05). In group I, mean rapid progress was found 11.81±7.76% in pretreatment group and 19.99±11.31% in post treatment. The difference was statistically significant (p<0.05). In group II, mean rapid progress was found 11.25±1.67% in pretreatment group and 11.4±1.59% in post treatment. The difference was not statistically significant (p>0.05). Conclusion: that sperm motility and rapid progress had significantly improved after three months’ treatment period with Ebastin than Placebo. Therefore, this study suggested that mast cell blocker ebastin can be helpful than placebo to improve the patients’ sperm motility with asthenozoospermia.
| Published in | Biomedical Sciences (Volume 7, Issue 2) |
| DOI | 10.11648/j.bs.20210702.11 |
| Page(s) | 41-46 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
Male Infertility, Mast Cell, Asthenozoospermia, Placebo, Ebastin
| [1] | Dohle GR, Colpi GM, Hargreave TB, Papp GK, Jungwirth A, Weidner W 2005. EAU guidelines on male infertility. Eur. Urol, vol. 48, no. 5, pp. 703–711. |
| [2] | Tuttelmann F, Nieschlag E 2009. Classification of andrological disorders. In: Andrology: Male Reproductive Health and Dysfunction. Nieschlag E, Behre HM, Nieschlag S (Eds). Springer, NY, USA, pp. 90–96. |
| [3] | Schuppe HC, Meinhardt A, Allam JP, Bergmann M, Weidner W, Haidl G 2008. Chronic orchitis: a neglected cause of male infertility? Andrologia, vol. 40, no. 2, pp. 84–91. |
| [4] | Haidl G, Allam JP, Schuppe HC 2008. Chronic epididymitis: impact on semen parameters and therapeutic options. Andrologia, vol. 40, no. 2, pp. 92–96. |
| [5] | Pejler G, Abrink M, Ringvall M, Wernersson S 2007. Mast cell proteases. Adv. Immunol, vol. 95, pp. 167–255. |
| [6] | Pejler G, Ronnberg E, Waern I, Wernersson S 2010. Mast cell proteases: multifaceted regulators of inflammatory disease. Blood, vol. 115, no. 24, pp. 4981–4990. |
| [7] | Schill WB, Schneider J, Ring J 1986. The use of ketotifen, a mast cell blocker, for treatment of oligo-and asthenozoospermia. Andrologia, vol. 18, no. 6, pp. 570–573. |
| [8] | Yamamoto M, Hibi H, Miyake K 1994. Appearance of spermatozoon after administration of mast cell blocker to a patient with azoospermia. Hinyokika Kiyo, vol. 40, no. 6, pp. 541–543. |
| [9] | Hibi H, Kato K, Mitsui K 2001. The treatment with tranilast, a mast cell blocker, for idiopathic oligozoospermia. Arch. Androl, vol. 47, no. 2, pp. 107–111. |
| [10] | Winters BR, Walsh TJ 2014. The Epidemiology of Male Infertility. Urol Clin N Am, vol. 41, pp. 195–204. |
| [11] | Chakraborty S, Bonthu N, Swanson BJ, Batra SK 2011. Role of mucins in the skin during benign and malignant conditions. Cancer Lett, vol. 301, pp. 127–41. |
| [12] | Roaiah MM, Khatab H, Mostafa T 2007. Mast cells in testicular biopsies of azoospermic men. Andrologia, vol. 39, no. 5, pp. 185–189. |
| [13] | Haidl G, Duan YG, Chen SJ, Kohn FM, Schuppe HC, Allam JP 2011. The role of mast cells in ale infertility. Expert Rev Clin Immunol, vol. 7, pp. 627–34. |
| [14] | Saharkhiz N, Nikbakht R and Hemadi M 2013. Ketotifen, a mast cell blocker improves sperm motility in asthenospermic infertile men. J Hum Reprod Sci, vol. 6, no. 1, pp. 19–22. |
| [15] | Multigner, L 2006, ‘Ketotifen improves sperm motility and sperm morphology in male patients with leukocytospermia and unexplained infertility’, Fertil Steril, vol. 85, pp. 240 –3. |
| [16] | Cayan S, Apa DD, Akbay E 2002. Effect of fexofenadine, a mast cell blocker, in infertile men with significantly increased testicular mast cells. Asian J. Androl, vol. 4, no. 4, pp. 291–294. |
| [17] | Hussein MR, Abou-Deif ES, Bedaiwy MA 2005. Phenotypic characterization of the immune and mast cell infiltrates in the human testis shows normal and abnormal spermatogenesis. Fertil. Steril, vol. 83, no. 5, pp. 1447–1453. |
| [18] | El-Karaksy A, Mostafa T, Shaeer OK, Bahgat DR, Samir N 2007. Seminal mast cells in infertile asthenozoospermic males. Andrologia, vol. 39, no. 6, pp. 244–247. |
| [19] | Ellem SJ, Wang H, Poutanen M, Risbridger GP 2009. Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am. J. Pathol, vol. 175, no. 3, pp. 1187–1199. |
| [20] | Hassa H, Yildirim A, Can C, Turgut M 2006. Effect of smoking on semen parameters of men attending an infertility clinic. Clin Exp Obstet Gynecol, vol. 33, pp. 19–22. |
| [21] | Mostafa T, Tawadrous G, Roaih MMF, Amer M, Ashour S, Aziz A 2006. Effect of smoking on seminal plasma ascorbic acid in infertile and fertile males. Andrologia, vol. 38, pp. 221–224. |
| [22] | Oliva A, Multigner L 2006. Ketotifen improves sperm motility and sperm morphology in male patients with leukocytospermia and unexplained infertility. Fertil. Steril, vol. 85, no. 1, pp. 240–243. |
| [23] | Moskovtsev SI, Willis J, White J, Mullen JB 2007. Leukocytospermia: Relationship to sperm deoxyribonucleic acid integrity in patients evaluated for male factor infertility. Fertil Steril, vol. 88, pp. 737–40. |
| [24] | Matsuki S, Sasagawa I, Suzuki Y 2000. The use of ebastine, a mast cell blocker, for treatment of oligozoospermia. Arch. Androl, vol. 44, no. 2, pp. 129–132. |
| [25] | Nagai T, Takaba H, Miyake K, Hirabayashi Y, Yamada K 1992. Testicular mast cell heterogeneity in idiopathic male infertility. Fertil. Steril, vol. 57, no. 6, pp. 1331–1336. |
| [26] | Yamamoto M, Hibi H, Miyake K 1995. New treatment of idiopathic severe oligozoospermia with mast cell blocker: results of a single-blind study. Fertil. Steril, vol. 64, no. 6, pp. 1221–1223. |
APA Style
Farzana Deeba, Jesmine Banu, Shakeela Ishrat, Shaheen Ara Anawary, Nurjahan Begum. (2021). Ebastine, a Mast Cell Blocker Improves Sperm Motility in Asthenospermic Infertile Men. Biomedical Sciences, 7(2), 41-46. https://doi.org/10.11648/j.bs.20210702.11
ACS Style
Farzana Deeba; Jesmine Banu; Shakeela Ishrat; Shaheen Ara Anawary; Nurjahan Begum. Ebastine, a Mast Cell Blocker Improves Sperm Motility in Asthenospermic Infertile Men. Biomed. Sci. 2021, 7(2), 41-46. doi: 10.11648/j.bs.20210702.11
AMA Style
Farzana Deeba, Jesmine Banu, Shakeela Ishrat, Shaheen Ara Anawary, Nurjahan Begum. Ebastine, a Mast Cell Blocker Improves Sperm Motility in Asthenospermic Infertile Men. Biomed Sci. 2021;7(2):41-46. doi: 10.11648/j.bs.20210702.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.bs.20210702.11,
author = {Farzana Deeba and Jesmine Banu and Shakeela Ishrat and Shaheen Ara Anawary and Nurjahan Begum},
title = {Ebastine, a Mast Cell Blocker Improves Sperm Motility in Asthenospermic Infertile Men},
journal = {Biomedical Sciences},
volume = {7},
number = {2},
pages = {41-46},
doi = {10.11648/j.bs.20210702.11},
url = {https://doi.org/10.11648/j.bs.20210702.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bs.20210702.11},
abstract = {Introduction: The right treatment of male infertility is relatively costly procedure. So we should sincerer about the treatment procedure to evaluate the role of mast cell blocker ebastin in male infertility for the sake of the wellbeing of our people. The study aims to observe and evaluate the effect of Mast cell (MC) blocker Ebastin in the improvement of sperm motility in asthenospermic infertile male. Methods: This was a longitudinal clinical trial study and was conducted in the Infertility Unit outdoor, Department of obstetrics and gynecology, Bangabandhu Sheikh Mujib Medical University, Dhaka. Bangladesh during the period from January 2015 to December 2015. This study was conducted among the male patients and followed Purposive sampling technique. Finally, 334 cases were enrolled in this study. Among the male with abnormal semen parameter 168 patients were Asthenozospermic and 60 patients were combined Oligo-asthenozospermic. Statistical analysis was carried out by using the SPSS 16.0 & MS-Excel2016. Result: From 334 study people we found in group I, mean sperm total mortality was 24.86±12.02% in pretreatment and 34.29±9.35% in post treatment. The difference was statistically significant (p0.05). Improved sperm motility was 75.4% of asthenozospermic male in ebastin group and 19.3% in placebo group. Which was statistically significant (p0.05). Conclusion: that sperm motility and rapid progress had significantly improved after three months’ treatment period with Ebastin than Placebo. Therefore, this study suggested that mast cell blocker ebastin can be helpful than placebo to improve the patients’ sperm motility with asthenozoospermia.},
year = {2021}
}
TY - JOUR T1 - Ebastine, a Mast Cell Blocker Improves Sperm Motility in Asthenospermic Infertile Men AU - Farzana Deeba AU - Jesmine Banu AU - Shakeela Ishrat AU - Shaheen Ara Anawary AU - Nurjahan Begum Y1 - 2021/05/14 PY - 2021 N1 - https://doi.org/10.11648/j.bs.20210702.11 DO - 10.11648/j.bs.20210702.11 T2 - Biomedical Sciences JF - Biomedical Sciences JO - Biomedical Sciences SP - 41 EP - 46 PB - Science Publishing Group SN - 2575-3932 UR - https://doi.org/10.11648/j.bs.20210702.11 AB - Introduction: The right treatment of male infertility is relatively costly procedure. So we should sincerer about the treatment procedure to evaluate the role of mast cell blocker ebastin in male infertility for the sake of the wellbeing of our people. The study aims to observe and evaluate the effect of Mast cell (MC) blocker Ebastin in the improvement of sperm motility in asthenospermic infertile male. Methods: This was a longitudinal clinical trial study and was conducted in the Infertility Unit outdoor, Department of obstetrics and gynecology, Bangabandhu Sheikh Mujib Medical University, Dhaka. Bangladesh during the period from January 2015 to December 2015. This study was conducted among the male patients and followed Purposive sampling technique. Finally, 334 cases were enrolled in this study. Among the male with abnormal semen parameter 168 patients were Asthenozospermic and 60 patients were combined Oligo-asthenozospermic. Statistical analysis was carried out by using the SPSS 16.0 & MS-Excel2016. Result: From 334 study people we found in group I, mean sperm total mortality was 24.86±12.02% in pretreatment and 34.29±9.35% in post treatment. The difference was statistically significant (p0.05). Improved sperm motility was 75.4% of asthenozospermic male in ebastin group and 19.3% in placebo group. Which was statistically significant (p0.05). Conclusion: that sperm motility and rapid progress had significantly improved after three months’ treatment period with Ebastin than Placebo. Therefore, this study suggested that mast cell blocker ebastin can be helpful than placebo to improve the patients’ sperm motility with asthenozoospermia. VL - 7 IS - 2 ER -
Information
Email: